Abstract
Background Endovascular coiling has become a routine modality for intracranial aneurysms. Scientific reports on the safety and feasibility of the Optima and OptiMAX coil system (Balt USA, LLC) are scarce in the neuro-interventional literature. We here report the first US experience of the early safety and outcome of using the Optima and OptiMAX coil system. Objective To report our single-center experience with Optima and OptiMAX Coil system in a series of consecutive patients having different neuroendovascular procedures Methods A retrospective, single-center analysis of an IRB-approved and prospectively maintained database was conducted. Patients between October 2020 and February 2023 undergoing neuroendovascular procedures with Optima and OptiMAX coil system were included. A total of 20 patients were involved in our series. Patient demographics, procedural details, Angiographic parameters, periprocedural complications, and Angiographic and clinical follow-up information were collected. Results A total of 20 patients were included. 70% (14/20) were females. The mean patient age was 53.55 ± 22.19 years. Of the patients treated 85% (17/20) were intracranial aneurysms (IA), 10% (2/20) were arteriovenous fistula (AVF), and 5% (1/20) were arteriovenous malformation (AVM). Of the aneurysmal cases, 5 patients presented with ruptured aneurysms. The majority of the aneurysms were located in the ICA (n= 11). The mean aneurysmal diameter was 6.72 ± 2.34. Coil system deployment was successful in all cases (n= 20). No Optima or OptiMAX Coils-related complications or adverse events were encountered. Complete aneurysmal obliteration, measured as Raymond- Roy class 1, was achieved in (n= 13) cases. Of the ruptured aneurysmal cases, (n=3) patients achieved Raymond Roy Class 2, and (n=1) achieved Raymond Roy class 3. On Follow-up, none of the patients showed aneurysmal recanalization or required retreatment. Conclusion Our early single-center experience demonstrates that Optima and OptiMAX Coil system is associated with high technical success and early safety profile in various neurovascular pathologies. A prospective, multicentric, and large sample size with long-term follow-up is warranted to confirm the findings of our study. Optima, OptiMAX, Coils, Embolization, Intracranial aneurysms Disclosures A. Abdelsalam: None. H. Fountain: None. M. Knott: None. M. Costello: None. T. Eatz: None. M. Silva: None. E. Wu: None. R. Starke: 1; C; Balt.